Compare Stocks: PTGX, BIIB, ALNY, and INSM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$222.10 -3.9%	$242.42	$197.81 ▼ $495.55	$29.72B	0.28	1.45 million shs	682,364 shs
BIIB Biogen	$220.43 -1.1%	$215.32	$138.00 ▼ $230.49	$32.57B	0.09	1.20 million shs	352,160 shs
INSM Insmed	$108.96 +0.3%	$120.12	$90.39 ▼ $212.75	$23.79B	0.83	2.90 million shs	1.96 million shs
PTGX Protagonist Therapeutics	$140.08 +0.6%	$145.09	$62.24 ▼ $160.81	$9.06B	1.53	710,938 shs	249,500 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-6.31%	-7.38%	-6.07%	-26.09%	-49.81%
BIIB Biogen	-1.35%	-1.56%	+3.14%	+3.10%	+44.48%
INSM Insmed	-4.86%	-10.66%	-10.63%	-2.70%	-26.27%
PTGX Protagonist Therapeutics	-1.21%	+1.35%	-4.98%	+5.75%	+117.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$222.10 -3.9%	$242.42	$197.81 ▼ $495.55	$29.72B	0.28	1.45 million shs	682,364 shs
BIIB Biogen	$220.43 -1.1%	$215.32	$138.00 ▼ $230.49	$32.57B	0.09	1.20 million shs	352,160 shs
INSM Insmed	$108.96 +0.3%	$120.12	$90.39 ▼ $212.75	$23.79B	0.83	2.90 million shs	1.96 million shs
PTGX Protagonist Therapeutics	$140.08 +0.6%	$145.09	$62.24 ▼ $160.81	$9.06B	1.53	710,938 shs	249,500 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-6.31%	-7.38%	-6.07%	-26.09%	-49.81%
BIIB Biogen	-1.35%	-1.56%	+3.14%	+3.10%	+44.48%
INSM Insmed	-4.86%	-10.66%	-10.63%	-2.70%	-26.27%
PTGX Protagonist Therapeutics	-1.21%	+1.35%	-4.98%	+5.75%	+117.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.83	Moderate Buy	$366.90	58.71% Upside
BIIB Biogen	2.56	Moderate Buy	$230.14	3.29% Upside
INSM Insmed	3.00	Buy	$200.57	84.70% Upside
PTGX Protagonist Therapeutics	2.89	Moderate Buy	$147.13	5.71% Upside

Current Analyst Ratings Breakdown

Latest PTGX, BIIB, ALNY, and INSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	ALNY Alnylam Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/30/2026	INSM Insmed	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$237.00 ➝ $207.00
9/30/2026	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$375.00 ➝ $369.00
9/24/2026	BIIB Biogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
9/24/2026	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$188.00
9/24/2026	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$188.00
9/21/2026	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$455.00
9/15/2026	INSM Insmed	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$212.00 ➝ $198.00
9/10/2026	BIIB Biogen	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$242.00
9/10/2026	BIIB Biogen	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Reduce	$165.00 ➝ $175.00
9/8/2026	ALNY Alnylam Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$230.00 ➝ $260.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	8.33	$2.62 per share	88.24	$5.97 per share	38.72
BIIB Biogen	$9.89B	3.33	$22.33 per share	9.98	$124.45 per share	1.79
INSM Insmed	$606.42M	39.10	N/A	N/A	$3.46 per share	31.38
PTGX Protagonist Therapeutics	$46.02M	195.72	N/A	N/A	$9.83 per share	14.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	42.97	23.83	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	39.44	13.83	2.49	8.32%	11.18%	6.88%	10/28/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	113.11	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	135.14	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)

Latest PTGX, BIIB, ALNY, and INSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	ALNY Alnylam Pharmaceuticals	$1.77	N/A	N/A	N/A	$1.43 billion	N/A
10/29/2026	Q3 2026	INSM Insmed	-$0.3911	N/A	N/A	N/A	$500.95 million	N/A
10/28/2026	Q3 2026	BIIB Biogen	$2.03	N/A	N/A	N/A	$2.64 billion	N/A
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BIIB Biogen	0.39	1.87	1.26
INSM Insmed	0.74	3.72	3.40
PTGX Protagonist Therapeutics	N/A	21.71	21.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
INSM Insmed	N/A
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
INSM Insmed	2.10%
PTGX Protagonist Therapeutics	5.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable
PTGX Protagonist Therapeutics	141	64.71 million	61.35 million	Optionable

PTGX, BIIB, ALNY, and INSM Headlines

Recent News About These Companies

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Rated "Moderate Buy" by Wall Street Brokerages

October 2 at 2:15 AM | americanbankingnews.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Consensus Price Target of $147.13 According to Analysts

October 2 at 2:13 AM | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - What's Next?

September 25, 2026 | marketbeat.com

1,324,498 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Bank of America Corp DE

September 18, 2026 | marketbeat.com

California State Teachers Retirement System Acquires 284 Shares of Protagonist Therapeutics, Inc. $PTGX

September 14, 2026 | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 11,200 Protagonist Therapeutics, Inc. $PTGX

September 13, 2026 | marketbeat.com

Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 7,278 Shares

September 11, 2026 | insidertrades.com

Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX

September 11, 2026 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $1,048,759.80 in Stock

September 10, 2026 | marketbeat.com

Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 54,174 Shares

September 10, 2026 | marketbeat.com

Dinesh Ph Patel Sells 63,548 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock

September 10, 2026 | marketbeat.com

Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Protagonist Therapeutics authorizes $300M share repurchase program

September 8, 2026 | msn.com

Protagonist Therapeutics Announces $300 Million Share Repurchase Program

September 8, 2026 | accessnewswire.comA

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 7, 2026 | marketbeat.com

Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status

September 6, 2026 | insidermonkey.com

MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?

September 4, 2026 | finance.yahoo.com

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)

September 2, 2026 | theglobeandmail.com

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Protagonist Therapeutics (PTGX)

September 2, 2026 | theglobeandmail.com

Research Analysts Offer Predictions for PTGX Q1 Earnings

September 2, 2026 | marketbeat.com

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026

September 2, 2026 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PTGX, BIIB, ALNY, and INSM Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$222.12 -9.06 (-3.92%)

As of 01:07 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$220.40 -2.42 (-1.08%)

As of 01:07 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Insmed NASDAQ:INSM

$108.99 +0.40 (+0.37%)

As of 01:07 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Protagonist Therapeutics NASDAQ:PTGX

$139.84 +0.65 (+0.47%)

As of 01:07 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PTGX, BIIB, ALNY, and INSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PTGX, BIIB, ALNY, and INSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PTGX, BIIB, ALNY, and INSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PTGX, BIIB, ALNY, and INSM Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Insmed NASDAQ:INSM

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PTGX, BIIB, ALNY, and INSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PTGX, BIIB, ALNY, and INSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PTGX, BIIB, ALNY, and INSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PTGX, BIIB, ALNY, and INSM Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Insmed NASDAQ:INSM

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools